Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
Go back to Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 28.90 +1.46 (5.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.44 | 52 Week High | $117.12 | |||
| Open | $27.56 | 52 Week Low | $46.52 | |||
| Day High | $29.09 | P/E | N/A | |||
| Day Low | $27.49 | EPS | $-1.97 | |||
| Volume | 1,026,357 | |||||
